Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
| ▸ | GNPAT | O15228 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30312562 | 0.90 | FOLH1 (0.43) | FOLH1GSRNOD1ERAP2ERAP1 | |
| SCHEMBL14763091 | 0.89 | GSR (0.42) | FOLH1GSRNOD1ERAP2ERAP1 | |
| SCHEMBL1900352 | 0.89 | GSR (0.42) | FOLH1GSRNOD1ERAP2ERAP1 | |
| SCHEMBL29371190 | 0.89 | FOLH1 (0.58) | FOLH1GSRERAP2ERAP1LNPEP | |
| SCHEMBL1308766 | 0.89 | FOLH1 (0.58) | FOLH1GSRERAP2ERAP1LNPEP | |
| SCHEMBL29617647 | 0.89 | FOLH1 (0.58) | FOLH1GSRERAP2ERAP1LNPEP | |
| SCHEMBL1308762 | 0.89 | FOLH1 (0.58) | FOLH1GSRERAP2ERAP1LNPEP | |
| SCHEMBL31384809 | 0.88 | GSR (0.49) | FOLH1GSRNOD1ERAP2ERAP1 | |
| SCHEMBL7570529 | 0.87 | DPP8 (0.51) | FOLH1GSRNOD1ERAP2ERAP1 | |
| SCHEMBL16421653 | 0.86 | FOLH1 (0.55) | FOLH1GSRNOD1ERAP2ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4110809-A1 | COMPOSITIONS AND METHODS | King's College London (GB) | 2023-01-04 | — | — | EP | disclosed |
| US-11358988-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200216498-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358988-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | FOLH1 550/4885GSR 1001/4885NOD1 447/4885 |
| US-20200216498-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | FOLH1 550/4885GSR 1001/4885NOD1 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.